Literature DB >> 19547926

Prokaryotic expression, purification and functional characterization of human FHL3.

Xin Huang1, Jinfeng Wang, Wenrong Xia, Minji Zou, Tao Xu, Zhe Jin, Xin Cai, Yuanyuan Wang, Jiaxi Wang, Donggang Xu.   

Abstract

Four and a half LIM domain protein 3 (FHL3) is a member of the family of LIM proteins and is involved in myogenesis, cytoskeleton reconstruction, cell growth and differentiation. The full-length FHL3 cDNA was cloned from human spleen cDNA library and inserted in a prokaryotic expression vector pBV220 and then the recombinant plasmid was transformed into E. coli JM109. The expression of the recombinant protein was induced at 42 degrees C. SDS-PAGE analysis showed that recombinant human FHL3 (rhFHL3) was mainly expressed as an inclusion body. After purification by HisTrap FF crude, the rhFHL3 was renatured by dialysis against renaturing buffer and identified by Western blot analysis using human FHL3 polyclonal antibody. The MTT assay showed that the purified rhFHL3 could inhibit HepG2 cell growth but promote the proliferation of ECV304 cells. In addition, the expression of angiogenin (Ang) gene was increased when ECV304 cells were pretreated with rhFHL3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19547926     DOI: 10.1007/s10529-009-0054-x

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  3 in total

1.  Production and Purification of a Novel Anti-TNF-α Single Chain Fragment Variable Antibody.

Authors:  Ali Akbar Alizadeh; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  Adv Pharm Bull       Date:  2015-12-31

Review 2.  The Roles of FHL3 in Cancer.

Authors:  Zhenjun Huang; Chengpeng Yu; Liqing Yu; Hongxin Shu; Xianhua Zhu
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

3.  Identification and characterization of MT-1X as a novel FHL3-binding partner.

Authors:  Xin Cai; Jinfeng Wang; Xin Huang; Wenliang Fu; Wenrong Xia; Minji Zou; Yuanyuan Wang; Jiaxi Wang; Donggang Xu
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.